Extended Data Fig. 2: Sensitivity of SARS-CoV-2 D614G, B.1.1.7 and B.1.351 variants to nasal swabs from early vaccine recipients.
From: Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies
a, Example of neutralization curves with nasal swab from one donor at week 3 (W3) post vaccination. No neutralization was detected. Similar results were obtained at the different times of sampling, up to W6 post-vaccination b, ED50 of neutralization of the three viral isolates, with nasal swabs from 16 vaccine recipients sampled at W2, W3 post first dose and then W1 and W3 post-second dose. The dotted line indicates the limit of detection (ED50 = 4). No neutralization was detected. Data are mean from two to four independent experiments. c,d, Analysis of the three COVID-19 vaccinated patients. Neutralizing antibody titers are shown in the serum (dotted line: ED50 = 30) and nasal swab (dotted line: ED50 = 4), at week 2 post vaccination e, Example of neutralization curves with nasal swab from one such COVID-19 vaccine recipient at week 2 post vaccination. Results are shown as mean ± SD from three independent experiments. f, Heat map summarizing the levels of anti-Spike antibodies and their neutralizing activity in the sera and nasal swabs of the 19 vaccinated individuals. Vac #17, 18 and 19 were previously infected by SARS-CoV-2. White boxes denote an absence of activity. n.d. = not determined.
